Servier Pharmaceuticals, shared on LinkedIn:
“Servier team members were proud to attend the American Brain Tumor Association 2026 National Conference, joining patients, caregivers, survivors, researchers, healthcare professionals, and advocates committed to advancing care for people affected by brain tumors.
Among the many important topics explored throughout the conference was the complexity of developing new drugs, devices and diagnostics for brain tumors. That was the focus of the panel discussion,
‘The Long Game: Inside the Complexities of Brain Tumor Drug, Device, and Diagnostics Development’ featuring Christelle Chacar, Oncology Medical Director at Servier.
Alongside fellow panelists, Christelle shared insights on the challenges – and opportunities – of advancing innovation for patients with brain tumors.
We’re grateful to ABTA for creating opportunities to learn, connect and engage with the broader brain tumor community as we work to move brain tumor care forward.”
Dolores Hambardzumyan: 2026 Berlin Marathon to Support American Brain Tumor Association
